BIO 2019 Notebook: Lartruvo Lookback, M&A Soars, BIO Vs. ASCO
Executive Summary
News and views from day four of the BIO International Convention: Former FDA official Amy McKee said "everything worked right" with accelerated approval and removal of Lilly's Lartruvo; emerging company M&A deals nearly double in 2018; and the ASCO effect on the 3-6 June BIO meeting.